Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of ...

"Johnson & Johnson discontinues Phase III study of treatment for bladder cancer" was originally created and published by ...

Researchers are a step closer to revolutionizing how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

J&J acquired rights to the silicone-based drug delivery service used in TAR-200, which allows for the continuous release of ...

Johnson & Johnson (JNJ) has discontinued a Phase 2 study of its drug TAR-200 for the treatment of muscle-invasive bladder ...

The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an ...

Pharma stock Theralase Technologies (TSXV:TLT) announced a significant update on its ongoing bladder cancer clinical study ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price ...

Research from Purdue University in collaboration with the National Institutes of Health (NIH) reveals that a cancer drug ...

TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development ...

A groundbreaking protocol promises significant advances for patients with bladder cancer. New therapeutic combinations show ...

Researchers are a step closer to revolutionising how doctors use radiotherapy to treat patients with muscle-invasive bladder ...